[1] George S, Rey N L, Reichenbach N, et al. α-Synuclein: the long distance runner[J]. Brain Pathol, 2013, 23(3):350-357. [2] Jellinger K A. Critical evaluation of the Braak staging scheme for Parkinson's disease[J]. Ann Neurol, 2010, 67(4):550. [3] Spillantini M G, Schmidt M L, Lee V M, et al. Alpha-synuclein in Lewy bodies[J]. Nature, 1997, 388(6645):839-840. [4] Baba M, Nakajo S, Tu P H, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies[J]. Am J Pathol, 1998, 152(4):879-884. [5] Ferrer I, Martinez A, Blanco R, et al. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease[J]. J Neural Transm, 2011, 118(5):821-839. [6] Sulzer D, Surmeier D J. Neuronal vulnerability, pathogenesis, and Parkinson's disease[J]. Mov Disord, 2013, 28(1):41-50. [7] Kalia L V, Kalia S K, McLean P J, et al. α-Synuclein oligomers and clinical implications for Parkinson disease[J]. Ann Neurol, 2013, 73(2):155-169. [8] Danzer K M, McLean P J. Drug targets from genetics: alpha-synuclein[J]. CNS Neurol Disord Drug Targets, 201, 10(6):712-723. [9] Park M J, Cheon S M, Bae H R, et al. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-nave patients with Parkinson's disease[J]. J Clin Neurol, 2011, 7(4):215-222. [10] El-Agnaf O M, Salem S A, Paleologou K E, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease[J]. FASEB J, 2006, 20(3):419-425. [11] Yu S, Li X, Liu G, et al. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody[J]. Neuroscience, 2007, 145(2):539-555. [12] 程芙蓉, 李昕, 殷娟娟, 等.过氧化氢和帕金森病患者血清促进α-突触核蛋白向线粒体与细胞核转运[J].首都医科大学学报, 2010, 31(6):732-736. |